Todd Davis: Ligand’s announcement on the FILSPARI full FDA approval

Todd Davis, CEO at Ligand Pharmaceuticals, shared on LinkedIn:

“We have had significant positive momentum across the Ligand Pharmaceuticals royalty portfolio in recent months. Yesterday marks another critical milestone with the full FDA approval for FILSPARI (sparsentan), developed by our long-term partner Travere Therapeutics for the treatment of IgA nephropathy, a rare progressive kidney disease that affects approximately 150,000 in the U.S. FILSPARI has become a key part of our royalty portfolio at Ligand which now includes 12 key commercial-stage products including treatments for cancer, COPD, kidney disease, and other rare conditions that impact billions of people globally.”

Read further.
Source: Todd Davis/Linkedin